KR101326472B1 - Composition for cleaning nasal cavity comprising mineral water - Google Patents

Abstract

The present invention relates to a composition for nasal washing containing mineral water as an active ingredient, in more detail the present invention is potassium 200 ~ 230mg / L, sodium 7000 ~ 9500mg / L, calcium 1400 ~ 1700mg / L as a mineral component , Magnesium 900 ~ 1100mg / L, zinc 3 ~ 9mg / L, strontium 25 ~ 35mg / L, selenium 200 ~ 500μg / L, vanadium 65 ~ 75μg / L, germanium 0.5 ~ 1.5μg / L, manganese 10-40 µg / L, Cobalt 1-3 µg / L, Titanium 600-950 µg / L, Copper 3-9 µg / L, Lithium 0.02-0.09 mg / L, Chlorine Ion 16000-19500 mg / L, Fluoride Nasal cleaning composition and rhinitis, comprising 1.5-3.0 mg / L, bromine ion 40-56 mg / L, sulfate ion 3000-4500 mg / L, boron 0.8-1.2 mg / L and silicon dioxide 0.5-15 mg / L, or It relates to a composition for preventing or treating sinusitis. The mineral water, which is an active ingredient of the nasal washing composition and the composition for the prevention or treatment of rhinitis or sinusitis, has the effect of reducing the swelling and thickness of the nasal mucosa caused by inflammation, and also improves the degree of inflammation. In addition, it is also effective in reducing the expression of substances that induce mucus hypersecretion, and can be widely used in the preparation of nasal washes and therapeutic agents and functional health foods that can improve, prevent and treat nasal disease symptoms such as sinusitis and rhinitis. .

Description

Composition for cleaning nasal cavity comprising mineral water

The present invention relates to a composition for washing the nasal cavity containing mineral water and a pharmaceutical composition capable of preventing or treating rhinitis and sinusitis.

Rhinitis refers to inflammation occurring in the nasal mucosa inside the nose, the respiratory tract of the human body, and includes viral and rhinitis caused by acute and chronic rhinitis and cold. Symptoms include a runny nose (a benign nasal mucus) and a stuffy nose (nasal obstruction). In general, infection with rhinitis not only causes difficulty breathing, but also causes symptoms such as headache or attention deterioration, which causes greater discomfort, and is rarely cured despite long-term treatment. The disease recurs afterwards, making treatment difficult.

In particular, allergic rhinitis or sinusitis causes chronic oxygen deficiency due to nasal congestion, which significantly reduces brain function. Therefore, children or adolescents with rhinitis or sinusitis often have chronic fatigue and learning disabilities, and even those with heavy workloads cause a lot of disruptions due to lower work efficiency.

In addition, the paranasal sinuses are located around the nose and filled with bone-filled air.The main paranasal sinuses are the frontal sinus located above both eyebrows, the maxillary sinus located on the face below both eyes, the ethmoid sinus located between both eyes, and the sphenoid sinus deep behind the nose. have. The paranasal sinuses are covered with the same type of mucosa as the nasal mucosa.The nasal and paranasal sinuses produce mucous secretions daily, from which the nasal secretions exit through the natural openings leading to the small sized pencil-holes in the nose. As it passes through, it has the function of filtering dust particles, bacteria and pollutants, and this mucus goes over the neck by a structure called millions of cilia that cover the nasal passages, and it is unconsciously swallowed by harmful substances or bacteria swallowed from above. It melts or dies. Since this is a normal function of our bodies, the average person does not feel the process. If the sinus outlet is blocked, mucus will accumulate and pus will develop due to secondary bacterial infection.

Therefore, the obstruction of the sinus outlet may be caused by anatomical causes, irritants, or allergies in the nose, and sinus disease may occur frequently in the same family, and stress may be a cause of chronic sinus disease as well as nasal obstruction. May cause excessive breathing in the lungs and make asthma worse.

Therefore, antiallergic or antihistamines are prescribed for the treatment of nasal diseases including rhinitis. However, antihistamines have side effects of frequent relapses and drowsiness, and topical steroids sprayed on the nose also eliminate symptoms at the moment of use, but they can cause sinusitis if used for a long time. . In addition, when the nasal congestion is severe, there is a problem that the laser surgery is expensive, which is expensive.

In addition, herbal medicine is acupuncture and aromatherapy, physiotherapy, drug therapy will be treated, these treatments also have a temporary symptomatic effect, it is not effective to cure rhinitis.

Recently, a mucosal immunity-promoting detergent composition technology containing a Korean mistletoe extract using natural extract as a nasal cleanser has been developed, but it is not easy to obtain an active ingredient and it is expensive. There is this.

Therefore, in order to effectively treat such kinds of rhinitis or sinusitis, it is necessary to properly wash the nasal cavity with a nasal detergent that is auxiliary and cost effective, and furthermore, a new and more effective and stable system for nasal disease and nasal disease treatment Is urgently needed.

It is an object of the present invention to provide a composition for nasal washing, containing mineral water.

It is also an object of the present invention to provide a composition for preventing or treating rhinitis or sinusitis containing mineral water.

In order to achieve the object of the present invention as described above, the present invention comprises a nasal wash composition comprising the marine mineral water taken from the 1100m underground of the hot spring area of the coastal Dangu district 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea as an active ingredient to provide.

In one embodiment of the present invention, the mineral water includes minerals such as potassium 200 to 230 mg / L, sodium 7000 to 9500 mg / L, calcium 1400 to 1700 mg / L, magnesium 900 to 1100 mg / L of manganese, 10 to 40 占 퐂 / L of manganese, 1 to 3 mg / L of manganese, 20 to 35 mg / L of strontium, 200 to 500 mu g / L of chlorine, 16000 to 19500 mg / L of chlorine ions, 1.5 to 3.0 mg / L of fluorine ions, 40 to 90 mg / L of bromine ions, 56 mg / L, sulfuric acid ions 3000 to 4500 mg / L, boron 0.8 to 1.2 mg / L and silicon dioxide 0.5 to 15 mg / L.

In one embodiment of the present invention, the mineral water is a concentrate, and the concentrate may contain 0.5 to 50% (v / v) based on the total weight of the composition.

In one embodiment of the present invention, the composition may be a liquid, paste, ointment, or spray formulation.

In addition, the present invention provides a composition for the prevention or treatment of rhinitis or sinusitis, including the marine mineral water taken from the 1100m underground of the hot spring area of the waterfront district 92-1 Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea.

In one embodiment of the present invention, the mineral water includes minerals such as potassium 200 to 230 mg / L, sodium 7000 to 9500 mg / L, calcium 1400 to 1700 mg / L, magnesium 900 to 1100 mg / L of manganese, 10 to 40 占 퐂 / L of manganese, 1 to 3 mg / L of manganese, 20 to 35 mg / L of strontium, 200 to 500 mu g / L of chlorine, 16000 to 19500 mg / L of chlorine ions, 1.5 to 3.0 mg / L of fluorine ions, 40 to 90 mg / L of bromine ions, 56 mg / L, sulfuric acid ions 3000 to 4500 mg / L, boron 0.8 to 1.2 mg / L and silicon dioxide 0.5 to 15 mg / L.

In one embodiment of the present invention, the mineral water is the mineral water is a concentrate, the concentrate may contain 0.5 to 50% (v / v) based on the total weight of the composition.

In one embodiment of the present invention, the mineral water may be to reduce the swelling of the intranasal mucosa due to inflammation, and to reduce the expression of MUC5AC gene, a mucus hypersecretion-inducing factor.

The composition for nasal washing and the composition for the prevention or treatment of rhinitis or sinusitis caused by inflammation, etc., containing marine mineral water taken from 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea according to the present invention It has the effect of reducing the swelling and thickness of the nasal mucosa, and also improves the degree of inflammation, and also has an excellent effect of reducing the expression of substances that induce mucus hypersecretion, thereby improving, preventing and improving nasal disease symptoms such as sinusitis and rhinitis. There is an effect that can be widely used in the manufacture of treatable nasal washes and therapeutic agents and functional health foods.

Figure 1 shows a microscopic view of the thickness of the nasal mucosa in rats induced by rhinosinusitis by LPS injection in the rat model, (a) is nothing treated, (b) saline solution Group treated with, (c) shows a group treated with LPS.
FIG. 2 shows a photograph of the same mouse group as shown in FIG. 1 when observed with a microscope, and the arrow indicates the site of the increased PAS.
Figure 3 shows the pictures observed by the Evans blue reagent staining effect on the vascular outflow due to inflammation in the same rat group as in Figure 1, the arrow shows the Evans blue staining with increased mucosal outflow.
Figure 4 shows a photograph observed by Evans blue reagent staining effect of inflammation due to mineral water treatment according to the present invention, A is a group not treated anything, B is a group treated only saline, C is LPS-treated group, D treated with LPS and saline, E treated with LPS and 25% mineral water, F treated with LPS and 50% (v / v) mineral water. One group, G, represents the group treated with LPS and 100% (v / v) mineral water,
5 is a result of measuring the degree of leakage of the Evans blue reagent according to each experimental group of Figure 4 measured by the absorbance.
Figure 6 shows the result of observing the nasal mucosa thickness of the microscope through hematoxylene-eosin staining after separating the nasal mucosa tissue from each rat group of FIG.
FIG. 7 shows the result of FIG. 6 as a bar graph.
8 is a mineral water according to the present invention in order to determine whether there is an effect of inhibiting the expression of the mucus hypersecretion inducing factor MUC5AC gene, after taking nasal tissue from each rat group of Figure 4, which can amplify the MUC5AC gene RT-PCR using the primers are shown.

The present invention is characterized in that it provides a new nasal cleaning composition comprising mineral water excellent in nasal washing effect and particularly excellent in reducing nasal mucosal edema and mucus hypersecretion due to inflammation. Mineral water contained as an active ingredient in the nasal cleaning composition according to the present invention is characterized in that it is marine mineral water taken from the 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea.

In general, seawater is called deep sea water by distinguishing it from surface water. Deep sea water refers to seawater less than 200 meters from the sea surface. It does not cause photosynthesis and contains many inorganic nutrients such as nitrogen, phosphorus and silicate It is known that it is not contaminated by air or chemical substances, and that it is not contaminated by solar and general bacteria, and that physical and chemical cleanliness is also excellent because of a small number of positive bacteria.

In addition, its temperature is low all year round, its stability is low, and its water temperature is stable. It contains essential trace elements and various mineral components in a balanced manner, and it is useful in the body such as excellent scavenging effect on active oxygen due to the action of dissolved metal ions. Has characteristics.

Therefore, the surface water is not suitable for use in the human body such as food and beverages in the present state of severe marine pollution. However, since deep sea water is not much in number in the surface layer and contains almost no pathogenic organisms, It can be said that the safety is extremely high.

On the other hand, nasal diseases caused by colds, sinusitis and allergic rhinitis cause headaches, sleep deprivation, coughing, stress, etc. in modern times, which greatly reduces the quality of life of the individual. It causes a loss of social costs. In the United States, recent statistics show that about 15% of the total population has sinusitis and about 30% have allergies, costing about $ 2.4 billion and $ 3.4 billion in medical costs annually. With the development of therapeutics, research on nasal lavage that can increase the therapeutic effect is increasing.

Nasal lavage is known to be a very effective way to improve mucus islet function, reduce swelling of the nasal mucosa, reduce the activity of inflammation-related factors and cleanse concentrated mucus (Tomooka LT et al., Clinical study and literature review of nasal irrigation. , Laryngoscope. 2000 Jul; 110 (7): 1189-93).

Therefore, the present inventors are developing a wash water that can wash the nasal cavity using marine mineral water, and marine mineral water, which is a deep seawater that is eluted from a rock bed of 1100m underground in the hot spring area, 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, Korea It was confirmed that the symptoms of the disease, mucosal edema, inflammatory factor activity and concentrated mucus removal effect is excellent, and that the mineral water is very suitable for use as a nasal cleaning composition.

That is, according to one embodiment of the present invention, after injecting the mineral water of the present invention into the rat nose in rats induced sinusitis with LPS, the vascular outflow due to the inflammatory flow path was stained with Evans blue dye, and as a result, nothing In comparison with the non-treated rats, LPS-induced rhinosinusitis significantly increased the outflow of Evans blue dye due to inflammation, and the outflow of Evans blue dye was reduced by the mineral water injection of the present invention. In particular, the group treated with 50% (v / v) and 100% (v / v) of the mineral water of the present invention has a higher outflow of Evans blue dye compared to the physiological saline treatment group used for nasal washing. It was found to be reduced (see FIGS. 3 and 4).

In another embodiment of the present invention, it was confirmed that the mineral water of the present invention has an effect of reducing nasal mucosa thickness, a symptom of nasal disease. As a result of thickness measurement through xylene-eosin staining, the nasal mucosa was significantly thicker than that of normal rats in which the rhinosinusitis was induced by LPS, whereas the mineral water of the present invention was increased due to LPS. The nasal mucosa thickness was shown to be reduced and this decrease was proportional to the concentration of treated mineral water (see FIGS. 5 and 6).

Therefore, through these results, the present inventors have found that the mineral water of the present invention can be used for nasal washing, which can prevent and improve nasal diseases caused by inflammation and allergy, and in particular, the mineral water of the present invention for nasal washing. It can be seen that when contained in more than 50% (v / v) based on the composition it can induce better efficacy.

Furthermore, the present inventors investigated whether the mineral water of the present invention can affect the causative factors of nasal diseases such as rhinitis and sinusitis. According to one embodiment of the present invention, MUC5AC is known to induce hypersecretion of mucus. The expression level of the factor was analyzed in the mouse models tested above. That is, after separating the nasal mucosa tissue from the group treated with physiological saline to LPS-induced rhinosinusitis-induced rhinosinusitis-treated rats and the rhinosinus-induced rats treated with mineral water of the present invention by concentration, RNA was extracted and the expression level of MUC5AC gene in each tissue was analyzed by RT-PCR using primers specific for MUC5AC gene. As a result, MUC5AC was used in the rat group that induced rhinosinusitis with LPS compared to the normal rat group that was not treated with anything. While the expression of the gene was increased by about three times or more, in the group treated with saline and mineral water of the present invention, the expression of the MUC5AC gene was found to be decreased compared to the rat group induced by rhinosinusitis with LPS, in particular physiological. Compared to the saline treatment group, the mineral water treatment group of the present invention was shown to more effectively reduce the expression of the MUC5AC gene. Was (see Fig. 6).

In general, within the conduction airways of the respiratory system, the mucosal ciliary system serves as the primary defense mechanism for transporting inhaled particles or infectious agents out of the airways. In addition, the substances present in the airway sera are known to limit the toxicity of the particles and to inactivate infectious agents, and the physical mechanism of coughing is known to play a role in draining mucus from the airway passages. In addition, the mucosal ciliary system consists of ciliary epithelial cells, epithelial goblet cells, and serous and mucous cells located in the submucosal gland, and the cilia are active transport of chloride and passive transport of water across the epithelium through the lumen of the airway passage. It is surrounded by an aqueous layer (peripheral fluid) secreted by it and comes into contact with the floating mucus on the aqueous layer and provides for the movement of the mucus by a constant propulsion action.

On the other hand, mucus generally promotes removal of inhaled particles or infectious agents, but hypersecretion of mucus causes various diseases such as chronic bronchitis, acute asthma, cystic fibrosis, rhinitis, sinusitis and bronchiectasis.

Therefore, in consideration of this, it was found that the mineral water of the present invention has an inhibitory effect on the expression of the MUC5AC gene that induces the production of mucus, thereby improving, preventing and treating the symptoms of nasal diseases such as rhinitis and sinusitis.

Therefore, the present invention can provide a nasal wash composition comprising the marine mineral water taken from the 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangneung-si, Gangwon-do, South Korea.

The mineral water contained as an active ingredient in the composition of the present invention contains, as minerals, 200 to 230 mg / L of potassium, 7000 to 9500 mg / L of sodium, 1400 to 1700 mg / L of calcium, 900 to 1100 mg / L of zinc, 25 to 35 mg / L of strontium, 200 to 500 μg / L of selenium, 65 to 75 μg / L of vanadium, 0.5 to 1.5 μg / L of germanium, 10 to 40 μg / 1 to 3 μg / L of titanium, 600 to 950 μg / L of titanium, 3 to 9 μg / L of copper, 0.02 to 0.09 mg / L of lithium, 16000 to 19500 mg / L of chlorine ion, 1.5 to 3.0 mg / Ions of 40 to 56 mg / L, sulfuric acid ions of 3000 to 4500 mg / L, boron of 0.8 to 1.2 mg / L and silicon dioxide of 0.5 to 15 mg / L.

As a result of analyzing the mineral components of the mineral water according to the present invention commissioned by the Korea Institute of Science and Technology (KIST), Korea Basic Science Research Institute (KBSI) and Korea Institute of Geoscience and Mineral Resources (KIGAM) Mineral waters are new and unknown.

In addition, in the present invention, the mineral water may be the marine mineral water itself taken at 1100 m underground of a hot spring area in the coastal area of Gangjin-ri, Gyeonggi-do, Gangneung-si, Gangneung-si, Korea. If the mineral water itself is used, (V / v) to 100% (v / v) based on the total weight of the composition, or in the form of concentrates, when used as a concentrate, 0.5 to 50% (v / v).

The concentrate may be a solid obtained by evaporating, concentrating and drying the mineral water according to the present invention, or may be a concentrate obtained by evaporating the natural mineral water, artificially desalting and drying (or evaporating) the natural mineral water.

Specifically, the concentrate of the mineral water according to the present invention can be produced by the following method. First, the raw water is collected and then filtered. In this case, the filtration step may be performed through several filtration steps. In the present invention, four filtration steps are performed. That is, the first step filtration was performed by removing the suspended matters having a particle size of more than 10 μm. Then, the suspended matters having a particle size of more than 5 μm were filtered out and then filtered. After sterilization by UV, the suspension of more than 0.2um was filtered out by a four step filtration process. The thus-obtained filtrate can be subjected to a desalting step and a drying step, and desalting is not limited thereto, but an electrodialyzer can be used.

Thereafter, the desalted powder is produced through natural drying or drying using a dry drier. In one embodiment of the present invention, a vacuum freeze dryer was used for the drying. In the final step, desalination powder can be pulverized and packaged.

In addition, the concentrate of mineral water according to the present invention can be produced by first concentrating raw water, drying it, and then performing a filtration step.

The nasal washing composition according to the present invention may further include a conventional therapeutic anti-allergic agent or anti-inflammatory agent suitable for improving nasal disease symptoms such as rhinitis and sinusitis, and also for flavoring, coloring, It may further include additives such as fungicides, antioxidants, preservatives, humectants, thickeners, inorganic salts, emulsifiers, synthetic polymer materials.

Furthermore, the administration method of the nasal washing composition according to the present invention is not limited thereto, but a spray method, a squeeze method, or an administration method by an electric machine may be used, and may be used in any formulation form, but is convenient for washing. It is preferable to be a liquid so that it may be manufactured and used also in paste form, ointment, spray formulations, etc.

Furthermore, the present invention can provide a composition for the prevention or treatment of rhinitis or sinusitis, which contains marine mineral water taken at 1100m underground from the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, Korea.

The composition of the present invention can be used as a pharmaceutical composition for the prophylaxis or treatment of nasal diseases such as rhinitis or sinusitis, when the concentrated mineral water according to the present invention is used in a concentration of 0.5 to 50% by weight relative to the total weight of the composition can do.

In addition, the composition for the prophylaxis or treatment of rhinitis or sinusitis according to the present invention comprises a pharmaceutically effective amount of mineral water itself or mineral water concentrate according to the present invention alone or at least one pharmaceutically acceptable carrier, excipient or diluent It may include. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, ameliorate or treat rhinitis or sinusitis. For example, the pharmaceutically effective amount of mineral water concentrate according to the invention is 0.5-100 mg / day / kg body weight, preferably 0.5-5 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on the symptom of the disease, the age, body weight, health condition, sex, administration route and treatment period of the patient.

In addition, "pharmaceutically acceptable" as used herein refers to a composition that is physiologically acceptable and does not normally cause an allergic reaction, such as gastrointestinal disorders, dizziness, or the like when administered to a human. Examples of such carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil. Further, it may further include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In addition, compositions for the prophylaxis and treatment of rhinitis or sinusitis of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.

The composition according to the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscular, and the dose of the active ingredient may be varied depending on various factors such as route of administration, age, sex, And the like.

In addition, the composition of the present invention can be administered in parallel with known compounds having the effect of preventing, improving or treating rhinitis or sinusitis.

Therefore, the present invention can provide a rhinitis or sinusitis medicament comprising a composition containing mineral water taken from 1100m underground in the hot spring area of Geumjin-ri Coastal Area.

Furthermore, the composition according to the present invention not only provides the excellent rhinitis or sinusitis inhibitory effect, but also is safer than conventional chemical preparations based on natural deep sea water, and does not have any toxic and side effects on the drug even when taken for a long time. Can be used with confidence.

Therefore, the composition of the present invention can be added to a food for the purpose of preventing or treating a disease caused by rhinitis or sinusitis, and thus can be used as a food composition for the prevention and improvement of disease symptoms caused by rhinitis or sinusitis. have.

In addition, it can be easily utilized as foods, such as the main ingredients, secondary ingredients, food additives, functional foods or beverages that are effective in preventing and improving disease symptoms caused by rhinitis or sinusitis.

In the present invention, the "food" means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing step, and a general meaning As used herein, it refers to food, food additives, functional foods and beverages.

Foods to which the composition according to the present invention can be added include, for example, various foods, beverages, gums, tea, vitamin complexes, and functional foods. In addition, in the present invention, the food may include special nutritive foods (e.g., crude oil, spirits, baby food, etc.), meat products, fish meat products, tofu, mackerel, noodles (Such as soy sauce, soybean paste, kochujang, mixed potatoes), sauces, confectionery (eg, snacks), candies, chocolate, gums, ice cream, milk products (eg, fermented milk, cheese, But are not limited to, pickled foods (various kinds of kimchi, pickles, etc.), beverages (e.g., fruit drinks, vegetable beverages, beverages, fermented beverages and the like) and natural seasonings (e.g. The food, beverage or food additive may be prepared by a conventional production method.

In addition, the term "functional food" refers to the control of biological defense rhythms and disease prevention of food groups or food compositions that have added value to the food by using physical, biochemical, or biotechnological techniques to act and express the function of the food for a specific purpose. It means a food that is designed and processed to fully express the body's regulatory function regarding recovery and the like, and specifically, it may be a health functional food. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In the present invention, the term "beverage " means a general term for drinking or enjoying a taste, and includes a functional beverage. The beverage contains, as the essential ingredient, the composition for treating and preventing rhinitis or sinusitis according to the present invention as an essential ingredient, and there are no special limitations, and various flavors or natural carbohydrates are added as in the general beverage. It may contain as a component.

Furthermore, the food containing the composition of the present invention in addition to the above-mentioned composition can be used as a food such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, And carbonates used in alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonated drinks, etc., and these components may be used independently or in combination Can be used.

In the food containing the composition of the present invention, the amount of the composition according to the present invention may be 0.001% by weight to 90% by weight, preferably 0.1% by weight to 40% by weight, And in the case of beverages, it may be contained in a proportion of 0.001 g to 2 g, preferably 0.01 g to 0.1 g based on 100 ml. However, in the case of long-term intake for health and hygiene purposes or for health control purposes, And since the active ingredient has no problem in terms of safety, it can be used in an amount of more than the above range, so it is not limited to the above range.

Therefore, the present invention can provide a health functional food for the prevention or improvement of rhinitis or sinusitis containing mineral water or mineral water concentrate according to the present invention as an active ingredient, the form of the food is not limited thereto, powder, It may be in the form of granules, tablets, capsules or beverages.

Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples. However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following Experimental Examples.

< Example  1>

The mineral water collecting and collecting method according to the present invention Concentrate  Produce

The present inventors collected the hot spring water taken from the 110m underground bedrock in the Geumjin-ri beach coastal area of Okgye-myeon, Gangneung-si, Gangneung-si, Gangwon-do, to collect mineral water that can be effectively used for nasal washing. After removing the contaminants, it was desalted using an electrodialysis machine (voltage: 5.5-7.5 V, electrode solution: 3% Na 2 SO 4, CJTTS-2-10 ED, Creative Techno). After the desalination was completed, the precipitate was filtered and dried using a vacuum freeze dryer (temperature: -40 to 30 ° C., degree of vacuum: 5 mTorr). The concentrate of the present invention prepared by this process was subjected to the following experiment Respectively.

< Example  2>

Rhinosinusitis  Induced Rat Model Fabrication

In order to determine whether the mineral water of the present invention according to Example 1 is suitable for use for nasal washing, and furthermore, it is possible to treat rhinitis diseases such as rhinosinusitis, a rat model in which rhinosinusitis is induced was produced. That is, 250 mg of healthy, respiratory disease-free Sprague Dawley rats, LPS, a factor inducing rhinosinusitis, was extracted from Pseudomonas aeruginosa (L-4524, Sigma, St. Louis, Mo, USA). / ml) and injected into the nose of the mouse in an amount of 0.1ml to produce a rat model in which rhinosinusitis was induced. At this time, the mice were raised in an environment free of pathogens, and were allowed to freely ingest sterile standard rat food (Ralston Purina, St. Louis, MO) and water. Animal experiments were conducted with the approval of the Catholic University Institutional Animal Care and Use Committee. At this time, the control was used to inject Saline (physiological saline) solution in the rat nose instead of LPS.

Thereafter, the induction of rhinosinusitis by LPS injection was confirmed through histological analysis and PAS staining that are used in the art for mucosal mucosa of rat nose.

As a result, as shown in Table 1, in the LPS-induced rhinosinusitis mice, the thickness of the nasal mucosa was found to be increased compared to the control group treated with saline, and the PAS staining area was also increased.

In addition, as shown in FIG. 1, after the LPS was injected into the rat nose, sinus mucosa was observed under a microscope after 4 days, and the LPS-injected group of the mucosa was compared to the group in which saline was added to the control group. As observed to increase in thickness, it was found that the rhinosinusitis rat model was well made by LPS treatment, and these results were also confirmed in the PAS staining results of FIG. 2.

< Example  3>

By mineral water administration according to the invention Rhinosinusitis  Symptom improvement and treatment effect analysis

In order to examine the disease treatment efficacy of the mineral water according to the present invention in the rhinosinusitis-induced rat model prepared by Example 2, the experimental rat group was divided as follows, and the following experiment was performed.

Classification of experimental mice Dosing solution rat A Does nothing Normal rat B Treats only saline Normal rat C Handles only LPS Rhinosinusitis-induced rats D LPS + saline solution Rhinosinusitis-induced rats E LPS + 25% Mineral Water Rhinosinusitis-induced rats F LPS + 50% Mineral Water Rhinosinusitis-induced rats G LPS + 100% Mineral Water Rhinosinusitis-induced rats

At this time, the 25%, 50% and 100% mineral water means that the mineral water prepared in Example 1 diluted with physiological saline such that 25% (v / v), 50% (v / v), 100% refers to 100% mineral water concentrate, wherein LPS was prepared as described in Example 2, and the treatment group of A ~ G used the dose of 0.1ml in the amount of the nose of the rat. Injected into.

As described above, the degree of plasma outflow was investigated in the rat group treated with each solution by using Evans blue reagent, which is measured by measuring the degree of staining because the plasma outflow increases when inflammation of the nasal cavity increases. It is used to analyze the degree of inflammation in the nasal cavity. The analysis of the degree of Evans blue effusion was first performed by injecting 1 ml of Evans blue solution (Sigma, 40 mg / ml in Salinee) into the external jugular vein of the rats, and after 1 minute of infusion, a nasal tissue sample was obtained from each rat. The sample was then immersed in 1 ml of formamide (Sigma, USA) for 24 hours at 60 ° C. Thereafter, the sample was centrifuged for 30 seconds at 9,000 rpm and 20 ° C., and then the absorbance of the supernatant obtained by centrifugation using a microplate reader (model 680, Biorad, USA) was measured at 630 nm.

As a result, as shown in Figure 3, the outflow of Evans blue due to inflammation appeared to be the most outflow of the rhinosinusitis-induced rat group (C) by LPS administration, while treating the normal saline used for conventional treatment In one group (D), the outflow degree was reduced compared to the C group, but the treated group of the mineral water of the present invention showed that the Evans blue outflow was reduced more than the physiological saline treatment group, especially 25% mineral water. Compared to the treated group (E), the effluent decreased more significantly in the groups treated with 50% mineral water and 100% mineral water (F and G). These results were also found through the results of FIG. 4 measured by the absorbance of Evans blue.

< Example  4>

Measurement of change in nasal mucosa thickness by mineral water administration according to the present invention

Nasal mucosa was collected from each rat in each rat group (A-G) tested in Example 3, and the thickness of the mucosa was analyzed by hematoxylin-eosin staining. Was fixed in 2% formalin, then fixed with 10% formalin liquid, embedded in paraffin, and then sliced into 5 micrometer thick microtome. After staining with hematoxylin-eosin (hematoxyline-eosin) was observed by light microscopy.

As a result, as shown in Figs. 5 and 6, in the rat group in which rhinosinusitis was induced by LPS, mucosal thickness was significantly increased compared to the rat group in which no rhinosinus was induced, and treated with LPS and saline. In the case of the group, the thickness of the mucosa was found to be reduced compared to the group treated with LPS alone, and the decrease in the thickness of the mucosa was similar to the group treated with 50% of the mineral water of the present invention, and the mineral water of the present invention was 100%. The treated group was found to have a lower mucosal thickness than the normal saline treated group.

< Example  5>

By mineral water of the present invention MUC5AC  Measures the effect of reducing gene expression

In the case of mucus hypersecretion of the airway, it is known that the MUC5AC gene is overexpressed. Therefore, when the expression of the MUC5AC gene is suppressed, excessive mucus secretion can be reduced to obtain a therapeutic effect of the disease caused by mucus hypersecretion.

In order to confirm whether the mineral water of the present invention has an activity of inhibiting the expression of the MUC5AC gene, the present inventors separated the nasal tissue from each rat group used in Example 3, extracted RNA from the tissue, and then extracted MUC5AC. The expression level of the MUC5AC gene was analyzed by performing RT-PCR using a primer capable of amplifying the gene. RNA was extracted using the extraction kit (iNtRON Biotechnology, Inc., Gyeonggi-do, Korea) according to the method proposed by the user, and PCR reaction for MUC5AC was performed at 95 ° C for 15 minutes and then at 94 ° C. The reaction was repeated 32 times of 1 minute at 55 ° C, 1 minute at 55 ° C, and 1 minute at 72 ° C. The PCR reaction of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was carried out at 94 ° C for 4 minutes and at 94 ° C. The reaction was repeated 35 times for 1 minute at 60 ° C. and 1 minute at 72 ° C. The primers used were designed by Gene Runner software (Hastings Software Inc., Las Vegas, Nev, USA). One was purchased from GenBenk, and the sequence of each primer is as follows.

Primer Sequence

MUC5AC forward primer; 5′-CATAGCCTCCTCTTGTTC-3 ′

MUC5AC reverse primer; 3′-ATTCCTGTAGCAGTAGTGAG-5 ′

GAPDH forward primer; 5′-GCTGGTGCTGAGTATGTCGT-3 ′

GAPDH reverse primer; 3′-GAATGGGAGTTGCTGTTGAA-5 ′

As a result, as shown in FIG. 7, the expression of the MUC5AC gene, which functions as a mucus hypersecretion, is significantly more than three times higher in the LPS-induced rhinosinusitis than in the non-treated group and the PBS-only group. In the group treated with saline with LPS and treated with mineral water of the present invention, the expression of MUC5AC gene was decreased compared to the group treated with LPS alone, and the mineral water treated group of the present invention. Was shown to decrease the expression of MUC5AC gene in proportion to mineral water concentration.

Therefore, through these experimental results, the present inventors have an effect of reducing the swelling and thickness of the nasal mucosa caused by inflammation, etc., in the case of mineral water according to the present invention, and also improves the degree of inflammation, MUC5AC inducing mucus hypersecretion It is also excellent in reducing the expression of the gene, it can be seen that it can be used as a nasal disease treatment and nasal wash water, such as sinusitis and rhinitis.

< Example  6>

Effect of improving rhinitis and sinusitis symptoms on mineral water of the present invention

The inventors of the present invention, to determine whether the mineral water according to the present invention can actually improve the symptoms of rhinitis and sinusitis patients, screening five patients for each experimental group three times a day determined by rhinitis and sinusitis at Catholic University St. Mary's Hospital (In morning weather, 2 pm, before bedtime) 10ml syringe was used to bow the head and the mineral water of the present invention was injected into the nasal cavity and waited for about 1 minute to let flow. This procedure was repeated for 10 days and the improved condition was evaluated on a 5 point scale on Day 5 and Day 10. In this case, the mineral water used was a solution containing 50% (v / v) of mineral water concentrate in water. The results are shown in Table 3 below. At this time, only the saline was used as a control group and saline used for nasal washing for improving the symptoms of conventional rhinitis.

Evaluation standard score Measure Symptom 0 No improvement at all Runny nose and very sneezing One Slightly improved Frequent stuffy nose and sneezing 2 Improved moderate Sometimes nasal congestion and sneezing 3 Much improved Almost no stuffy nose and sneezing 4 Fully improved No stuffy nose or sneezing at all

Improvement of rhinitis and sinusitis symptoms Saline solution Saline solution Mineral water of the present invention 0 days 0.1 0.1 0.1 5 days 0.1 1.3 2.2 10 days 0.2 2.2 3.6

Symptom improvement effect of the disease caused by mineral water of the present invention in rhinitis and sinusitis patients, as shown in Table 3, the degree of symptom improvement of disease compared to the case of using the conventional saline solution, the mineral water of the present invention Was found to be superior.

So far I looked at the center of the preferred embodiment for the present invention. Those skilled in the art will appreciate that the present invention is not limited to the embodiments disclosed herein,

It will be understood that the invention may be embodied in various other forms without departing from the spirit or essential characteristics thereof. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.

Claims (8)

It was taken from the 1100m underground area of the coastal hot spring area of 92-1 Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea. , Magnesium 900 ~ 1100mg / L, zinc 3 ~ 9mg / L, strontium 25 ~ 35mg / L, selenium 200 ~ 500μg / L, vanadium 65 ~ 75μg / L, germanium 0.5 ~ 1.5μg / L, manganese 10-40 µg / L, Cobalt 1-3 µg / L, Titanium 600-950 µg / L, Copper 3-9 µg / L, Lithium 0.02-0.09 mg / L, Chlorine Ion 16000-19500 mg / L, Fluoride Rhinitis containing 1.5-3.0 mg / L, bromine ion 40-56 mg / L, sulfate ion 3000-4500 mg / L, boron 0.8-1.2 mg / L and silicon dioxide 0.5-15 mg / L, or Nasal washing pharmaceutical composition for the prevention or treatment of sinusitis. delete The method of claim 1,
The mineral water is a desalted and evaporated concentrate, and the concentrate is 0.5 to 50% (v / v) based on the total weight of the composition, nasal wash for the prevention or treatment of rhinitis or sinusitis, characterized in that Pharmaceutical composition for. The method of claim 1,
The composition is a nasal washing pharmaceutical composition for the prevention or treatment of rhinitis or sinusitis, characterized in that the liquid, paste, ointment, or spray formulations. delete delete delete The method of claim 1,
The mineral water reduces the swelling of the intranasal mucosa due to inflammation, and the nasal washing pharmaceutical composition for the prevention or treatment of rhinitis or sinusitis, characterized in that it has an effect of reducing the expression of the mucin hypersecretion inducing factor MUC5AC gene.

Images